Nucleix

About:

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.

Twitter/X: nucleix2

Top Investors: BlackRock, RA Capital Management, OrbiMed, Sands Capital Ventures, Lilly Asia Ventures

Description:

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Total Funding Amount:

$83M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Rehovot, HaMerkaz, Israel

Founded Date:

2008-01-01

Contact Email:

info(AT)nucleix.com

Founders:

Adam Wasserstrom, Danny Frumkin, Elon Ganor

Number of Employees:

11-50

Last Funding Date:

2022-01-05

IPO Status:

Private

Industries: